| scholarly article | Q13442814 |
| P50 | author | Craig W. Lindsley | Q67215429 |
| Carlos L Arteaga | Q88735105 | ||
| Ana Maria Gonzalez-Angulo | Q107718318 | ||
| Bryan T. Hennessy | Q117214243 | ||
| Gordon B. Mills | Q28086262 | ||
| P2093 | author name string | Olle Stål | |
| Archana Narasanna | |||
| J Phillip Kennedy | |||
| Todd W Miller | |||
| Gizeh Pérez-Tenorio | |||
| Marta Guix | |||
| Marianela Pérez-Torres | |||
| P2860 | cites work | Induction of ErbB-3 expression by alpha6beta4 integrin contributes to tamoxifen resistance in ERbeta1-negative breast carcinomas | Q21144348 |
| AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor | Q22254314 | ||
| Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN | Q24322051 | ||
| P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase | Q24322705 | ||
| Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity i | Q44294727 | ||
| Estrogen receptor-alpha regulates the degradation of insulin receptor substrates 1 and 2 in breast cancer cells | Q44488193 | ||
| Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. | Q54031538 | ||
| A role for Akt in mediating the estrogenic functions of epidermal growth factor and insulin-like growth factor I | Q73274526 | ||
| Neuregulin induces the rapid association of focal adhesion kinase with the erbB2-erbB3 receptor complex in schwann cells | Q73754429 | ||
| PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration | Q24677034 | ||
| PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer | Q27860985 | ||
| FAK integrates growth-factor and integrin signals to promote cell migration | Q28144169 | ||
| PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms | Q28181035 | ||
| Insulin and insulinomimetic agents induce activation of phosphatidylinositol 3'-kinase upon its association with pp185 (IRS-1) in intact rat livers | Q28188075 | ||
| PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma | Q28243071 | ||
| Inactivation of platelet-derived growth factor receptor by the tumor suppressor PTEN provides a novel mechanism of action of the phosphatase | Q28567492 | ||
| The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism | Q29547302 | ||
| Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase | Q29617567 | ||
| Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity | Q29618117 | ||
| Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase | Q30439814 | ||
| Role of receptor complexes in the extranuclear actions of estrogen receptor alpha in breast cancer | Q30442765 | ||
| Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors | Q31142952 | ||
| ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines | Q33928631 | ||
| Insulin-like growth factor I-induced degradation of insulin receptor substrate 1 is mediated by the 26S proteasome and blocked by phosphatidylinositol 3'-kinase inhibition | Q33962150 | ||
| FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells | Q33986318 | ||
| The mitogenic action of insulin-like growth factor I in normal human mammary epithelial cells requires the epidermal growth factor receptor tyrosine kinase. | Q34273711 | ||
| Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. | Q34463159 | ||
| Phosphorylation of human progesterone receptors at serine-294 by mitogen-activated protein kinase signals their degradation by the 26S proteasome | Q34999960 | ||
| Nongenomic actions of steroid hormones | Q35038285 | ||
| ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms. | Q35049847 | ||
| Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. | Q35757521 | ||
| Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast | Q35788322 | ||
| Src promotes estrogen-dependent estrogen receptor alpha proteolysis in human breast cancer | Q35868817 | ||
| Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities | Q36778493 | ||
| Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance | Q36860992 | ||
| Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer | Q36877180 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| FAK signaling is critical for ErbB-2/ErbB-3 receptor cooperation for oncogenic transformation and invasion | Q40353474 | ||
| Type I transforming growth factor beta receptor binds to and activates phosphatidylinositol 3-kinase. | Q40469680 | ||
| Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. | Q40587498 | ||
| Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells | Q40588061 | ||
| Effect of estradiol on estrogen receptor-alpha gene expression and activity can be modulated by the ErbB2/PI 3-K/Akt pathway. | Q40635044 | ||
| Cell cycle arrest by the PTEN tumor suppressor is target cell specific and may require protein phosphatase activity | Q40768754 | ||
| Inhibition of estrogen-induced breast cancer cell proliferation by reduction in autocrine transforming growth factor alpha expression | Q41425061 | ||
| Estradiol Formation from Testosterone by Continuously Cultured Human Breast Cancer Cells* | Q41687520 | ||
| In vivo antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase | Q42799629 | ||
| Identification of the JNK signaling pathway as a functional target of the tumor suppressor PTEN. | Q42807109 | ||
| Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells | Q43539817 | ||
| Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer | Q43675669 | ||
| PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer | Q43700699 | ||
| P433 | issue | 10 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | breast cancer | Q128581 |
| preproinsulin | Q7240673 | ||
| P304 | page(s) | 4192-201 | |
| P577 | publication date | 2009-05-15 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Loss of Phosphatase and Tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer | |
| P478 | volume | 69 |
| Q35810031 | A comprehensive analysis of phosphatase and tensin homolog deleted on chromosome 10 (PTEN) loss in colorectal cancer |
| Q41895474 | A novel role for PTEN in the inhibition of neurite outgrowth by myelin-associated glycoprotein in cortical neurons |
| Q26824462 | A paradigm shift: Cancer therapy with peptide-based B-cell epitopes and peptide immunotherapeutics targeting multiple solid tumor types: Emerging concepts and validation of combination immunotherapy |
| Q58763282 | A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer |
| Q52727619 | ATM inhibition induces synthetic lethality and enhances sensitivity of PTEN-deficient breast cancer cells to cisplatin. |
| Q38973005 | Amplification of SOX4 promotes PI3K/Akt signaling in human breast cancer |
| Q38165914 | Androgen receptor expression and outcomes in early breast cancer: a systematic review and meta-analysis |
| Q37783931 | Approaches and limitations of phosphatidylinositol-3-kinase pathway activation status as a predictive biomarker in the clinical development of targeted therapy |
| Q37690969 | Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation |
| Q37255088 | Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications |
| Q37585095 | Biological determinants of endocrine resistance in breast cancer |
| Q37947909 | Biological mechanisms and clinical implications of endocrine resistance in breast cancer |
| Q37168778 | Biomarkers of response to Akt inhibitor MK-2206 in breast cancer |
| Q34989077 | Can phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibition ERase them all? |
| Q38028797 | Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy? |
| Q37718221 | Clinical outcomes based on multigene profiling in metastatic breast cancer patients |
| Q52951832 | Combined Inhibition of Both p110α and p110β Isoforms of Phosphatidylinositol 3-Kinase Is Required for Sustained Therapeutic Effect in PTEN-Deficient, ER+ Breast Cancer. |
| Q41520280 | Cryptotanshinone inhibition of mammalian target of rapamycin pathway is dependent on oestrogen receptor alpha in breast cancer |
| Q36255950 | Cudraflavone C Induces Tumor-Specific Apoptosis in Colorectal Cancer Cells through Inhibition of the Phosphoinositide 3-Kinase (PI3K)-AKT Pathway |
| Q36703783 | Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer |
| Q34103963 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention |
| Q26778349 | Dosing and Safety Implications for Oncologists When Administering Everolimus to Patients With Hormone Receptor-Positive Breast Cancer |
| Q36854062 | Emerging therapeutic targets in metastatic progression: A focus on breast cancer |
| Q59072640 | Endocrine Resistance in Breast Cancer |
| Q37200831 | ErbB3 downregulation enhances luminal breast tumor response to antiestrogens |
| Q93078802 | Eribulin Synergistically Increases Anti-Tumor Activity of an mTOR Inhibitor by Inhibiting pAKT/pS6K/pS6 in Triple Negative Breast Cancer |
| Q55339569 | Estrogen receptor alpha drives mTORC1 inhibitor-induced feedback activation of PI3K/AKT in ER+ breast cancer. |
| Q92626410 | Estrogen therapy induces an unfolded protein response to drive cell death in ER+ breast cancer |
| Q28085004 | Everolimus plus exemestane for the treatment of advanced breast cancer: a review of subanalyses from BOLERO-2 |
| Q99408601 | Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations |
| Q42473573 | F344/NTac Rats Chronically Exposed to Bromodichloroacetic Acid Develop Mammary Adenocarcinomas With Mixed Luminal/Basal Phenotype and Tgfβ Dysregulation. |
| Q36287691 | Frequency of mesenchymal-epithelial transition factor gene (MET) and the catalytic subunit of phosphoinositide-3-kinase (PIK3CA) copy number elevation and correlation with outcome in patients with early stage breast cancer |
| Q39269303 | Functional inactivation of Rb sensitizes cancer cells to TSC2 inactivation induced cell death |
| Q37200505 | Functional proteomics characterization of residual triple-negative breast cancer after standard neoadjuvant chemotherapy |
| Q35201923 | HER-3 peptide vaccines/mimics: Combined therapy with IGF-1R, HER-2, and HER-1 peptides induces synergistic antitumor effects against breast and pancreatic cancer cells |
| Q38725101 | HER3 as a Therapeutic Target in Cancer |
| Q39368710 | HER3 comes of age: new insights into its functions and role in signaling, tumor biology, and cancer therapy |
| Q36957145 | HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation. |
| Q37334563 | Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway |
| Q35709435 | High basal Wnt signaling is further induced by PI3K/mTor inhibition but sensitive to cSRC inhibition in mammary carcinoma cell lines with HER2/3 overexpression |
| Q44850155 | Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen |
| Q37734101 | Human Epidermal Growth Factor Receptor-3 mRNA Expression as a Prognostic Marker for Invasive Duct Carcinoma not Otherwise Specified |
| Q33968076 | Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer |
| Q92714699 | Impact of next-generation sequencing (NGS) for primary endocrine resistance in breast cancer patients |
| Q42508996 | Insulin growth factor receptor-1 expression and loss of PTEN protein predict early recurrence in triple-negative breast cancer |
| Q35145443 | LYN-activating mutations mediate antiestrogen resistance in estrogen receptor-positive breast cancer |
| Q38034816 | Mechanisms of acquired resistance to targeted cancer therapies. |
| Q36589865 | Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance. |
| Q38778550 | Metabolomics in Breast Cancer: Current Status and Perspectives |
| Q35861503 | Mutations in the phosphatidylinositol 3-kinase pathway: role in tumor progression and therapeutic implications in breast cancer |
| Q36188758 | Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer |
| Q33843662 | Northwestern profiling of potential translation-regulatory proteins in human breast epithelial cells and malignant breast tissues: evidence for pathological activation of the IGF1R IRES. |
| Q36420373 | Overcoming Endocrine Resistance in Hormone-Receptor Positive Advanced Breast Cancer-The Emerging Role of CDK4/6 Inhibitors |
| Q35000243 | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. |
| Q39561017 | Overcoming resistance to fulvestrant (ICI182,780) by downregulating the c-ABL proto-oncogene in breast cancer |
| Q35288044 | P-REX1 creates a positive feedback loop to activate growth factor receptor, PI3K/AKT and MEK/ERK signaling in breast cancer. |
| Q35690099 | PAX2 is activated by estradiol in breast cancer cells of the luminal subgroup selectively, to confer a low invasive phenotype |
| Q54989589 | PET Imaging on Dynamic Metabolic Changes after Combination Therapy of Paclitaxel and the Traditional Chinese Medicine in Breast Cancer-Bearing Mice. |
| Q35038068 | PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer. |
| Q39425843 | PI3K/AKT pathway regulates phosphorylation of steroid receptors, hormone independence and tumor differentiation in breast cancer |
| Q37092758 | PTEN mutation, methylation and expression in breast cancer patients |
| Q34394399 | Palbociclib (PD 0332991) : targeting the cell cycle machinery in breast cancer |
| Q36116250 | Peptide vaccines and targeting HER and VEGF proteins may offer a potentially new paradigm in cancer immunotherapy |
| Q91660651 | Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation |
| Q26862550 | Phosphatidylinositol 3-kinase and antiestrogen resistance in breast cancer |
| Q33925164 | Pictilisib for oestrogen receptor-positive, aromatase inhibitor-resistant, advanced or metastatic breast cancer (FERGI): a randomised, double-blind, placebo-controlled, phase 2 trial. |
| Q58793646 | Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers |
| Q37639114 | Progesterone receptor isoform-specific promoter methylation: association of PRA promoter methylation with worse outcome in breast cancer patients |
| Q37632170 | Progress with palbociclib in breast cancer: latest evidence and clinical considerations |
| Q92237404 | Prospects for pharmacological targeting of pseudokinases |
| Q34659897 | RB-pathway disruption in breast cancer: differential association with disease subtypes, disease-specific prognosis and therapeutic response |
| Q64055629 | Recent advances of therapeutic targets based on the molecular signature in breast cancer: genetic mutations and implications for current treatment paradigms |
| Q35734750 | Role of insulin-like growth factor-1 signaling pathway in cisplatin-resistant lung cancer cells |
| Q35127249 | SU2C phase Ib study of paclitaxel and MK-2206 in advanced solid tumors and metastatic breast cancer |
| Q36230591 | Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in BXPC-3 and PANC-1 human pancreatic cancer cells |
| Q36863266 | Strategically Timing Inhibition of Phosphatidylinositol 3-Kinase to Maximize Therapeutic Index in Estrogen Receptor Alpha-Positive, PIK3CA-Mutant Breast Cancer |
| Q35312683 | Targeting PTEN-defined breast cancers with a one-two punch |
| Q34995919 | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. |
| Q36336601 | The changing role of ER in endocrine resistance |
| Q55435506 | The impact of PI3K inhibitors on breast cancer cell and its tumor microenvironment. |
| Q33862290 | The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer |
| Q38090432 | The regulatory roles of phosphatases in cancer |
| Q27852764 | Therapeutic targeting of cancers with loss of PTEN function |
| Q30419997 | Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer |
| Q54324226 | Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. |
Search more.